Radiolabeled hTAB004 (Therapeutic)
Triple-Negative Breast Cancer
PreclinicalActive
Key Facts
About OncoTAb
OncoTAb is a private, pre-revenue biotech company leveraging its patented tMUC1-targeting antibody platform to address unmet needs in oncology. Its initial focus is the commercial launch of the Agkura Personal Score, a blood-based diagnostic test for breast cancer detection in women with dense breasts, which represents a significant market opportunity. Beyond diagnostics, the company has a preclinical pipeline exploring the same targeting agent for therapeutic applications, including radioimmunotherapy and CAR-T cell therapies for breast and pancreatic cancers.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| RejuverSen Antibody | Centenara Labs | Pre-Clinical |
| FlowVax BreastCA | Flow Pharma | Pre-clinical |
| Undisclosed circRNA Program | CircNova | Pre-clinical |
| AI Predictor for TNBC | PathomIQ | Development/Validation |
| TNBC Biomarker/Target Discovery | CogNano | Preclinical (Mouse Studies) |